Susquehanna International Group
SCLN

Susquehanna International Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Susquehanna International Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,900
Closed -$129K – 10693
2016
Q4 		$129K Buy
+11,900
New +$119K ﹤0.01% 8951
2016
Q3 		– Sell
-13,400
Closed -$175K – 9474
2016
Q2 		$175K Buy
+13,400
New +$176K ﹤0.01% 7716
2015
Q1 		– Sell
-27,500
Closed -$241K – 10316
2014
Q4 		$241K Sell
27,500
-4,700
-15% -$38K ﹤0.01% 8502
2014
Q3 		$222K Buy
+32,200
New +$193K ﹤0.01% 8509
2014
Q1 		– Sell
-24,300
Closed -$122K – 9726
2013
Q4 		$122K Buy
24,300
+4,600
+23% +$22.1K ﹤0.01% 8558
2013
Q3 		$100K Sell
19,700
-75,900
-79% -$423K ﹤0.01% 8085
2013
Q2 		$474K Buy
+95,600
New +$455K ﹤0.01% 6119

Other funds holding SCLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group's SCLN Position: Q3 2017 in Review

Susquehanna International Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 12,901 shares — an estimated $142K sold.

Susquehanna International Group first reported a position in SCLN in Q3 2013 and held it in 13 quarters. The position peaked at $1.92M in Q2 2015. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Susquehanna International Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Susquehanna International Group sold 12,901 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $142K.
  • Susquehanna International Group first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 13 quarters.
  • Susquehanna International Group's Sciclone Pharmaceuticals Inc position peaked at $1.92M in Q2 2015.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Susquehanna International Group's 13F filing for Q3 2017, filed 14 Nov 2017.